Literature DB >> 11906760

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Anthony H Choi1, Monica M McNeal, Jason A Flint, Mitali Basu, Nils Y Lycke, John D Clements, Judy A Bean, Heather L Davis, Michael J McCluskie, John L VanCott, Richard L Ward.   

Abstract

Intranasal (i.n.) immunization of BALB/c mice with chimeric murine rotavirus EDIM (epizootic diarrhea of infant mice) VP6 and attenuated E. coli heat-labile toxin (LT), LT(R192G), stimulated >99% protection against rotavirus shedding after EDIM challenge. Here, we evaluated other potential adjuvants with chimeric VP6 administered by two mucosal routes: i.n. and oral. Besides LT(R192G), the adjuvants examined included Adjumer, CpG oligodeoxynucleotides (CpG ODN), chimeric A1 subunit of cholera toxin (CTA1)-DD, and QS-21. All except QS-21 significantly (P<0.05) increased VP6-specific serum IgG responses after i.n. immunization, but none significantly increased these responses when administered orally. The i.n. delivery of chimeric VP6 alone induced both rotavirus IgG1 and IgG2a whose relative titers suggested a skewed Th2-like response. Inclusion of Adjumer greatly increased Th2-like responses, while CpG ODN shifted the response to a less Th2-like response. The adjuvants CTA1-DD, LT(R192G), QS-21 had no significant effect on ratios of IgG1/IgG2a titers. Following EDIM challenge of mice immunized i.n. with chimeric VP6 and either LT(R192G), CTA1-DD, Adjumer or CpG ODN, shedding was reduced >99, 95, 80, 74, respectively, relative to that found in unimmunized mice (P<0.05). QS-21 induced less protection (43%, not significant (N.S.)) while immunization with chimeric VP6 alone reduced shedding by only 16% (N.S.). Oral immunization with chimeric VP6 and all selected adjuvants except QS-21 was less effective than after i.n. immunization, with protection levels of 94 (P<0.05), 71 (P<0.05), 55, 35 and 28% for LT(R192G), QS-21, CpG ODN, CTA1-DD, and Adjumer, respectively, while immunization with chimeric VP6 alone gave no protection. Thus, different adjuvants induced different degrees of protection and oral immunization was generally less effective then the i.n. route.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906760     DOI: 10.1016/s0264-410x(02)00043-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.

Authors:  Nathalie Parez; Cynthia Fourgeux; Ali Mohamed; Catherine Dubuquoy; Mathieu Pillot; Axelle Dehee; Annie Charpilienne; Didier Poncet; Isabelle Schwartz-Cornil; Antoine Garbarg-Chenon
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.

Authors:  Anthony H-C Choi; Kristi Smiley; Mitali Basu; Monica M McNeal; Mingyuan Shao; Judy A Bean; John D Clements; Richard R Stout; Richard L Ward
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

4.  Prevention of the murine model of biliary atresia after live rotavirus vaccination of dams.

Authors:  Alexander J Bondoc; Mubeen A Jafri; Bryan Donnelly; Sujit K Mohanty; Monica M McNeal; Richard L Ward; Greg M Tiao
Journal:  J Pediatr Surg       Date:  2009-08       Impact factor: 2.545

5.  HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.

Authors:  Andrea S Laimbacher; Laura E Esteban; Alejandro A Castello; Juan C Abdusetir Cerfoglio; Marcelo H Argüelles; Graciela Glikmann; Alejandra D'Antuono; Nora Mattion; Mabel Berois; Juan Arbiza; Monika Hilbe; Elisabeth M Schraner; Michael Seyffert; Christiane Dresch; Alberto L Epstein; Mathias Ackermann; Cornel Fraefel
Journal:  Mol Ther       Date:  2012-06-19       Impact factor: 11.454

6.  Defining T-cell-mediated immune responses in rotavirus-infected juvenile rhesus macaques.

Authors:  K Sestak; M M McNeal; A Choi; M J Cole; G Ramesh; X Alvarez; P P Aye; R P Bohm; M Mohamadzadeh; R L Ward
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Adherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.

Authors:  Mohamed D Abd Alla; Gary L White; Tyson B Rogers; Max E Cary; David W Carey; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2007-05-25       Impact factor: 3.441

8.  Analysis of immune response in young and aged mice vaccinated with corn-derived antigen against Escherichia coli heat-labile enterotoxin.

Authors:  Sule Karaman; Joan Cunnick; Kan Wang
Journal:  Mol Biotechnol       Date:  2006-01       Impact factor: 2.695

Review 9.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

10.  Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

Authors:  Connor P O'Meara; Charles W Armitage; Marina C G Harvie; Peter Timms; Nils Y Lycke; Kenneth W Beagley
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.